Related Experiment Video
Updated: Jan 30, 2026

Isolation and Identification of Waterborne Antibiotic-Resistant Bacteria and Molecular Characterization of their Antibiotic Resistance Genes
Published on: March 3, 2023
[Experimental models: interactions Synercid and beta-lactam antibiotics]
1CHUV Lausanne.
Unlabelled:
SYNERCID ALONE IN A RAT MODEL OF EXPERIMENTAL ENDOCARDITIS: Trials conducted using 2 injections daily showed that animals infected with meti-R resistant Staphylococcus aureus strains sensitive to erythromycin were cured in 3 days. The same is not true for infections caused by C-MLSB-R staphylococci. The daily dose cannot be increased due to the venous toxicity of Synercid, leading to the idea of testing Synercid in combination with other antibiotics.
In Vitro Studies:
Several antibiotics have been tested in combination with Synercid. Several beta-lactams have been shown to exhibit an additive or synergetic effect on a collection of meti-R and meti-S S. aureus strains.
In Vivo Studies:
In animals infected with C-MLSB-R meti-R S. aureus, the combination Synercid + cefepime increases the activity of cefipime and prevents selection of beta-lactam highly resistant strains. The results obtained with the Synercid + cefpirome combination are even more eloquent. Finally, Synercid, alone or in combination with these 2 cephalosporins, does not select resistant strains.
Insights
Synercid effectively treated experimental endocarditis in rats caused by certain Staphylococcus aureus strains. However, combinations with beta-lactam antibiotics like cefepime and cefpirome showed improved efficacy and prevented resistance development.
Area of Science:
- Microbiology
- Pharmacology
- Infectious Diseases
Context:
- Experimental endocarditis models are crucial for evaluating antibiotic efficacy against Staphylococcus aureus.
- Synercid (quinupristin/dalfopristin) demonstrated limited efficacy against certain resistant strains.
- Venous toxicity of Synercid restricts dose escalation, necessitating combination therapy.
Purpose:
- To investigate the efficacy of Synercid alone and in combination with beta-lactam antibiotics against Staphylococcus aureus endocarditis in a rat model.
- To assess the potential of antibiotic combinations to overcome Synercid's limitations and prevent resistance development.
Summary:
- Synercid monotherapy achieved rapid cure in rats infected with methicillin-resistant Staphylococcus aureus (MRSA) sensitive to erythromycin but failed against clindamycin, erythromycin, and other macrolides, lincosamides, and streptogramins B resistant (C-MLSB-R) strains.
- In vitro studies revealed additive or synergistic effects of several beta-lactams when combined with Synercid against both methicillin-resistant (MRSA) and methicillin-susceptible (MSSA) S. aureus strains.
- In vivo, the Synercid + cefepime combination enhanced cefepime activity and prevented the selection of highly resistant strains in rats infected with C-MLSB-R MRSA. The Synercid + cefpirome combination yielded even more potent results. Crucially, Synercid, alone or combined with these cephalosporins, did not select for resistant strains.
Impact:
- Combination therapy with Synercid and specific beta-lactams offers a promising strategy to enhance treatment outcomes for Staphylococcus aureus endocarditis, particularly against resistant strains.
- This approach may help mitigate the emergence of antibiotic resistance, a significant global health concern.
- The findings support the development of novel therapeutic regimens for complex bacterial infections where monotherapy is insufficient.
Related Concept Videos
Development of Antibiotic Resistance
Antibiotic Selection
Experimental Determination of Chemical Formula
Experimental RNAi
Experimental Designs
Predator-Prey Interactions

